- Home
- DHT vs AUPH Comparison
DHT vs AUPH Comparison
Compare DHT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | AUPH |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | Bermuda | Canada |
| Employees | N/A | 128 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DHT | AUPH |
|---|---|---|
| Price | $17.77 | $14.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $16.33 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 6.2M | 973.0K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $8.85 | $16.53 |
| Revenue Next Year | N/A | $16.24 |
| P/E Ratio | $12.73 | ★ $6.75 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $9.00 | $6.83 |
| 52 Week High | $20.55 | $16.54 |
Technical Indicators
Market Signals| Indicator | DHT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 52.82 |
| Support Level | $10.96 | $14.56 |
| Resistance Level | $20.55 | $15.23 |
| Average True Range (ATR) | 0.73 | 0.47 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 47.23 | 54.32 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.